The recall of Heparin sodium vial products has widened to include a broader recall of the product. American Health Packaging (AHP), subsidiary of the world’s largest pharmaceutical services companies AmerisourceBergen, announced a voluntary recall of 1,421 units (25 vials per unit) of heparin sodium injection vials. The vials were manufactured by Baxter then placed by AHP into individual labeled bags for use in pharmacy automation equipment. The packages were then sold to five hospitals in Georgia and California. Patients have experienced numerous side effects including abdominal pain, burning sensation, chest pain, diarrhea, dizziness, drug ineffectiveness, dyspepsia, dyspnia, erythema, flushing, headache, hyperhidrosis, hypoesthesia, hypotension, including profound and refractory hypotension, increased lacrimation, loss of consciousness, malaise, nausea, pallor, palpitations, paresthesia, paresthesia (oral), pharyngeal adema, restlessness, vomiting/retching, stomach discomfort, tachycardia, thirst, trismus, and unresponsiveness to stimuli. The reports of profound and refractory hypotension usually occur with the first few minutes of bolus administration. It has been discovered that the recalled products contained oversulfated condroitin sulfate that were contaminated by manufacturers in China.